Free tool
Drug literature search
Last checked: Nov 20, 2026Source: PubMed, Europe PMC, OpenAlex
1,700 results in Europe PMC
PubMed plus preprints and full-text open access papers. Showing the first 25. Limited to clinical trials, meta-analyses and systematic reviews.
- Prognostic value of anti-gp210 antibodies in primary biliary cholangitis: A Systematic review and meta-analysis.
Zhang Y, Jin Y, Wang M, Pan K, Xu A. · Medicine (Baltimore) · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- The role of linerixibat in treating pruritus in primary biliary cholangitis: A systematic review and meta-analysis of randomised controlled trials.
Kumar M, Kumar V, Warisha S, Kumar S, Khan M, Gulbahar M, Shabbir S, Kumar L, Nasir RB, Rafique U, Pamnani MK, Farwa UE, Indra S, Poonam F, Bakhtawar F, Chaulagain A. · Medicine (Baltimore) · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Safety profile of elafibranor versus placebo in primary biliary cholangitis: A systematic review, meta-analysis, and trial sequential analysis of randomized controlled trials.
Khan NA, Shahbaz H, Talha M, Khan MA, Tahir MA, Anwar U, Khan MA, Adhikari P. · Medicine (Baltimore) · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Meta-Analysis: PPAR Agonists for Pruritus and Quality of Life in Primary Biliary Cholangitis.
Martins A, Khakoo NS, Corpechot C, Rousseau A, Reynolds JM, Kremer AE, Murad MH, Sultan S, Levy C. · Aliment Pharmacol Ther · 2026 · cited 1 timesmeta-analysis, systematic review
- Symptom burden and treatment patterns in primary biliary cholangitis: A systematic review and meta-analysis.
Chung AH, Tan JJ, Yap RXJ, Loo JH, Tay WX, Singh CL, Ong SJ, Low AYJ, Lin Y, Lytvyak E, Mason A, Montano-Loza AJ, Wong YJ. · Hepatol Commun · 2026 · cited 0 timesOpen accessmeta-analysis, systematic review
- Gut microbiota alterations in primary biliary cholangitis: a systematic review and meta-analysis.
Qianlang R, Yanxin Z, Dejia X, Guoqing W, Lihong L, Hang C, Xianmei W, Junyan L, Lanqing M. · Front Microbiol · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- Glucosyl Hesperidin Benefits in Primary Biliary Cholangitis: A Multicenter, Open-Label, Randomized Controlled Study.
Moriya K, Asada K, Ozu N, Suzuki S, Fujinaga Y, Enomoto M, Tsuji Y, Komeda Y, Hanatani J, Kaya D, Matsuo Y, Nagamatsu S, Matsuo H, Uejima M, Yamazaki M, Yoshiji H. · Clin Transl Gastroenterol · 2026 · cited 0 timesOpen accessmulticenter study, randomized controlled trial
- Clinical, safety, and patient-reported outcomes associated with second-line and later therapies in primary biliary cholangitis: A systematic review.
Carbone M, Jones D, Solanke O, Brandt R, Krause T, Asquith D, Pashley A, Shaw S, Worthington E, Schattenberg JM. · Hepatol Commun · 2026 · cited 0 timesOpen accesssystematic review, review-article
- Dose Reduction of Ursodeoxycholic Acid in Primary Biliary Cholangitis Patients With Complete Biochemical Response: An Open-Label Randomized Clinical Trial.
He C, Wei Y, Zheng K, Wang X, Liu J, Li M, Wang L, Zhang F. · J Gastroenterol Hepatol · 2026 · cited 0 timesrandomized controlled trial
- Long-Term Safety and Efficacy of Obeticholic Acid in Patients With Primary Biliary Cholangitis: Final Results of the POISE Long-Term Safety Extension.
Bowlus CL, Nevens F, Kowdley KV, Bonder A, Capozza T, Li J, Nair R, Trauner M, Jones DE. · Aliment Pharmacol Ther · 2026 · cited 1 timesOpen accessclinical trial, phase iii, multicenter study
- Diagnostic potential of salivary biomarkers for primary biliary cholangitis: a systematic review.
Saeed M, Shaikh MS, Binhezaim A, Almutairi T, Lone MA, Bukhari SJA, Zafar MS. · Front Med (Lausanne) · 2025 · cited 0 timesOpen accesssystematic review, systematic-review
- Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVE.
Levy C, Bowlus CL, Lawitz E, Antunes N, Miller B, Shu J, Zein CO, Kowdley KV. · Liver Int · 2026 · cited 3 timesOpen accessclinical trial, phase iii, research support, non-u.s. gov't
- Seladelpar in patients with primary biliary cholangitis and compensated cirrhosis: Efficacy and safety from RESPONSE and ASSURE studies.
Gordon SC, Villamil A, Jacobson IM, Lawitz EJ, Lawitz EJ, Younes Z, Silveira MG, Bowlus CL, Drenth JPH, Vierling JM, Morgera U, Vasura A, Dalekos G, Galli A, Rabinovitz M, Heo J, Nevens F, Levy C, Zhou Y, Carroll S, Crittenden DB. · Hepatol Commun · 2026 · cited 1 timesOpen accessclinical trial, phase iii, randomized controlled trial
- Comparative efficacy and safety of ursodeoxycholic acid, fibrates, and combination therapy in primary biliary cholangitis: an umbrella meta-analysis of meta-analyses.
Zhang J, Xiu T, Shen Q. · Front Pharmacol · 2026 · cited 0 timesOpen accesssystematic review, systematic-review
- Prevalence of Celiac Disease in Patients With Primary Biliary Cholangitis: A Systematic Review and Meta-Analysis.
Zingone F, Canova C, Forss A, Ebrahimi F, Cazzagon N, Rosato I, Ludvigsson JF. · Liver Int · 2025 · cited 3 timesOpen accessmeta-analysis, systematic review
- Network meta-analysis: relative clinical efficacy and safety of elafibranor versus seladelpar as second-line treatment for patients with primary biliary cholangitis.
Jones D, Combe E, Knight H, Laskier-Owens V, Ren S, Wright T, Böing EA, Pashley A. · J Comp Eff Res · 2026 · cited 1 timesOpen accessresearch support, non-u.s. gov't, systematic review
- Seladelpar Improved Itch, Itch-Related Sleep Disturbance and Measures of Fatigue in Patients With Primary Biliary Cholangitis and Pruritus in the Phase 3 RESPONSE Trial.
Levy C, Jones DEJ, Mayo MJ, Bowlus CL, Kowdley KV, Hirschfield GM, Liu J, Burk C, Carroll S, Crittenden DB, Kremer AE. · Aliment Pharmacol Ther · 2026 · cited 4 timesOpen accessclinical trial, phase iii, research support, non-u.s. gov't
- Recurrent primary biliary cholangitis after liver transplantation: A global meta-analysis of epidemiology and risk factors.
Passos PRC, Filho VOC, Noronha MM, Rossi YI, Vitor IC, Tomé MR, Amador WFO, Silveira IB, Leite MABC, Motta RV, Cançado GGL. · Am J Transplant · 2026 · cited 1 timesmeta-analysis, systematic review
- Efficacy and Safety of Obeticholic Acid as Second-Line Therapy in Primary Biliary Cholangitis: Systematic Review and Meta-Analysis.
Abreu ES, Fernandes GP, Lacerda HC, Reginato PH, Ferreira Neves HA, Sanchez Gonzalez CD, Eaton JE, Cançado GGL. · J Gastroenterol Hepatol · 2025 · cited 5 timesmeta-analysis, systematic review
- The Genomics/Genetics of Primary Biliary Cholangitis: The Case for a Functional SNP rs10893900 in ETS1/FLI1 and Review of the Literature.
Zhang M, Wang C, Huang Y, Wang L, Dai Y, Jiang Y, Han C, Gong Y, Li L, Tian Y, Tian W, Lin R, Tong S, Wang M, Ma X, Qiu F, Lian Z, Gershwin ME, Shi X, Chen W, Liu X. · Clin Rev Allergy Immunol · 2025 · cited 0 timesmeta-analysis, review
- Genetic architecture of primary biliary cholangitis: strong evidence for HLA and non-HLA risk loci.
Zhang M, Lyu L, Ge L, Wang Y, Gu D. · Front Immunol · 2025 · cited 1 timesOpen accessmeta-analysis, systematic review
- Global Epidemiology of Primary Biliary Cholangitis: An Updated Systematic Review and Meta-Analysis.
Tan JJ, Chung AH, Loo JH, Quek JWE, Sharma S, Singh CL, Yap RXJ, Tay WX, Smith MK, Lytvyak E, Mason A, Montano-Loza AJ, Wong YJ. · Clin Gastroenterol Hepatol · 2026 · cited 9 timesmeta-analysis, systematic review
- Optimising Primary thErapy in pRimAry biliary cholangitis (OPERA): protocol for a randomised, double-blind, placebo-controlled trial of enhanced primary therapy with obeticholic acid.
Dunn S, Evans L, Kennedy C, Wafer R, Moody S, Wolstenhulme F, Burton E, Konkoth AB, Fisher H, Chadwick T, Banham A, Hale F, Christie M, Barclay ST, Dyson J, Smith R, Aithal G, Culver E, Aspinall R, Thorburn D, Heneghan M, Hancock HC, Trivedi P, Mells G, Wason J, Jones DEJ. · BMJ Open · 2026 · cited 0 timesOpen accessclinical trial protocol
- Fatigue in people with primary biliary cholangitis: a position paper from the European Reference Network for Rare Liver Diseases.
Koc OM, Toussaint AK, Untas A, Milkiewicz P, Ytting H, Buck L, Jones DE, Hirschfield G, Leburgue A, Schramm C, Nevens F, van der Meer AJ, Gerussi A, Verbeek J. · Lancet Gastroenterol Hepatol · 2026 · cited 11 timesmeta-analysis, research support, non-u.s. gov't
- An experimental study on the effect of symptom expectations on mental fatigue and motivation in people with primary biliary cholangitis.
Buck L, Herzberg J, Lenaert B, Löwe B, Hartl J, Schramm C, Toussaint A. · Sci Rep · 2025 · cited 0 timesOpen accessrandomized controlled trial
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.